← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 100.0% to $0, while Net income decreased 401.4% to ($10.8M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $0Watch
- Profitability — Net income ($10.8M)Watch
- Cash generation — Free cash flow ($10.1M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
KIORA PHARMACEUTICALS INC: In July 2024, we were granted Orphan Medicinal Product Designation by the European Medicines Agency for KIO-301 for the treatment of non-syndromic, rod-dominant retinal dystrophies, which includes diseases like retinitis pigmentosa, choroideremia, Stargardt disease and others.
Where the revenue comes from
Fiscal 2024, as KIORA PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
Leadership changes
From KIORA PHARMACEUTICALS INC's own filings, the day they're filed.
- Carmine Stengone · director · appointmenteff. 2023-08-01
- Erin Parsons · Chair of the Compensation Committee · appointment
- Carmine Stengone · Chairman · appointment
Latest filings
- 8-K · Company announcement2026-08-19
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about KIORA PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.